Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Synergistic antiviral composition and use thereof

A composition and virus technology, applied in the field of immunology, can solve problems such as inability to achieve therapeutic treatment

Inactive Publication Date: 2012-08-29
MARINOMED BIOTECHNOLOGIE GMBH
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, effective curative treatment does not currently appear to be available for patients who have been symptomatic for more than 2 days

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synergistic antiviral composition and use thereof
  • Synergistic antiviral composition and use thereof
  • Synergistic antiviral composition and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1: iota-carrageenan and TAMIFLU in mice treated 48 hours after infection synergistic therapeutic effect.

[0053] Lethal dose (10xLD) was utilized by intranasal instillation (i.n.) without anesthesia 50 ) of influenza A / PR / 8 / 34 virus infected 40C57BI6 mice. Following nasal infection, the virus spread into the respiratory tract and eventually caused fatal pneumonia in mice. The model simulates natural influenza infection in humans via the respiratory tract, which sometimes leads to severe illness.

[0054] The mice were divided into four groups with 10 mice in each group. Forty-eight hours after infection, mice were treated twice daily with intranasal instillation without anesthesia, where the first group received placebo treatment (25 μl of 0.5% NaCl in water per nostril) as a negative control, and the second group received only Each nostril was treated with 25 μl of an aqueous solution of iota-carrageenan polymer at a concentration of 1200 μg / ml. Groups...

Embodiment 2

[0057] Example 2: iota-carrageenan and TAMIFLU in mice treated 24 hours after infection synergistic therapeutic effect.

[0058] Due to TAMIFLU (oseltamivir phosphate) is known to be most effective when treatment is initiated within 24 hours of the first symptoms of infection, so it was analyzed whether combination treatment with iota-carrageenan could improve TAMIFLU of therapeutic efficacy. Due to the use of TAMIFLU Treatment already provided a high degree of protection against lethal outbreaks of the disease, so average animal weight was used as a surrogate parameter to assess animal health. Animal weights were compared using a t-test. The experiments were carried out as described in Example 1, with the only difference that the treatment was started up to 24 hours after infection.

[0059] like figure 2 As shown, all animals suffered from weight loss due to lethal influenza virus infection. While using TAMIFLU (black circles) or iota-carrageenan (black squar...

Embodiment 3

[0060] Example 3: Synergistic therapeutic effect of iota-carrageenan and oseltamivir in mice treated 48 hours after infection.

[0061]Infection of mice was accomplished as described in Example 1. The mice were divided into four groups with 10 mice in each group. Forty-eight hours after infection, mice were treated twice daily with intranasal instillation without anesthesia, where the first group received placebo treatment (25 μl of 0.5% NaCl in water per nostril) as a negative control, and the second group received doses of Oral treatment with oseltamivir at 5 mg / kg / day, the third group was treated with 25 μl of an aqueous solution of iota-carrageenan polymer at a concentration of 1200 μg / ml in each nostril, and the fourth group was treated with iota-carrageenan twice a day. - combination therapy of carrageenan and oseltamivir, wherein oseltamivir is administered orally at a dose of 5 mg / kg / day, and the total amount of intranasally administered iota-carrageenan is 100 μl, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Login to View More

Abstract

The present invention relates to iota- and / or kappa-carrageenan in combination with a neuraminidase inhibitor for use as a medicament in the prophylactic or therapeutic treatment of a symptom, condition or disease caused by or associated with an infection by an influenza virus.

Description

technical field [0001] The invention belongs to the field of immunology and relates to the application of combination of carrageenan and neuraminidase inhibitor for preventive treatment or therapeutic treatment of influenza virus infection. Background technique [0002] Structurally, carrageenans are complex clusters of polysaccharides composed of repeating galactose-related monomer units. Currently, three major types of carrageenans are identified, namely, lambda, kappa, and iota carrageenans. [0003] The antiviral effects of iota- and kappa-carrageenan against Orthomyxoviridae, Paramyxoviridae and Coronaviridae have been previously described in WO2009 / 027057. The antiviral effects of iota- and kappa-carrageenan against rhinovirus infection have been previously described in WO2008 / 067982. These polymers have been shown to be useful in the preparation of antiviral pharmaceutical compositions suitable for delivery to the mucous membranes of the respiratory tract. [0004]...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/13A61K31/19A61K31/731
CPCA61K31/13A61K31/19A61K31/731A61K45/06A61K47/36A61P11/00A61P11/02A61P11/06A61P11/08A61P29/00A61P31/12A61P31/16A61P37/08A61P43/00A61K2300/00
Inventor 安德里亚·格拉索尔伊娃·普里斯赫-格拉索尔克里斯蒂安娜·迈尔M·考尼格-舒斯特尔
Owner MARINOMED BIOTECHNOLOGIE GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com